UPCC 37420 Phase 2 Study of Belantamab Mafodotin As Pre- and Post- Autologous Stem Cell Transplant Consolidation and Maintenance For Multiple Myeloma
Brief description of study
The research study is being conducted to see if combining an investigational drug, called belantamab mafodotin, with standard-of-care autologous stem cell transplant and maintenance therapy in patients with myeloma can help reduce the amount of myeloma cells that can be detected in patients after transplant. We will also study if this drug is safe to give both before and after autologous stem cell transplant as well as with maintenance therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 844252
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
